Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor Up for MHLW Panel Review on Nov. 25; 2 More Indications for Keytruda Also on Agenda

A key health ministry advisory committee will discuss whether to recommend approval for a batch of new medicines on November 25 including Bayer Yakuhin’s darolutamide for the treatment of castration-resistant prostate cancer (CRPC). Filed in Japan in March, darolutamide, otherwise...read more